[Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches]

Dtsch Med Wochenschr. 2005 Apr 22;130(16):1020-5. doi: 10.1055/s-2005-866780.

[Article in German]

Authors

K Spiekermann¹, W Hiddemann, S Schnittger

Affiliation

¹ Klinische Kooperationsgruppe "Leukämie" und Labor für Leukämiediagnostik, Medizinische Klinik III, Klinikum Grosshadern der Ludwig-Maximilians-Universität München und GSF-Hämatologikum, München. [email protected]

PMID: 15830315
DOI: 10.1055/s-2005-866780

No abstract available

Publication types

Review

MeSH terms

Biomarkers, Tumor / genetics*
Biomarkers, Tumor / metabolism
Biomarkers, Tumor / physiology
Enzyme Inhibitors / therapeutic use
Gene Expression Regulation, Neoplastic
Hematopoiesis / genetics
Hematopoiesis / physiology
Humans
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / therapy
Mutation*
Proto-Oncogene Proteins / antagonists & inhibitors
Proto-Oncogene Proteins / genetics*
Proto-Oncogene Proteins / metabolism
Proto-Oncogene Proteins / physiology
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
Receptor Protein-Tyrosine Kinases / genetics*
Receptor Protein-Tyrosine Kinases / metabolism
Receptor Protein-Tyrosine Kinases / physiology
fms-Like Tyrosine Kinase 3

Substances

Biomarkers, Tumor
Enzyme Inhibitors
Proto-Oncogene Proteins
FLT3 protein, human
Receptor Protein-Tyrosine Kinases
fms-Like Tyrosine Kinase 3